Jeffrey Yordon - 03 Aug 2022 Form 4 Insider Report for Athenex, Inc.

Reporting relationship: COO, and President, Athenex Pharmaceutical Division.
Issuer ticker: N/A
Reported as of: 03 Aug 2022
Net transaction value: -$2,127
SEC form: 4
Accepted by SEC: 15 Aug 2022, 17:34:39 UTC
Prior SEC filing: 21 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/Staci Holquist, Attorney-in-Fact

Key filing fact

Jeffrey Yordon filed Form 4 for Athenex, Inc. on 15 Aug 2022.

Key facts

This page summarizes Jeffrey Yordon's Form 4 filing for Athenex, Inc..
3 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 15 Aug 2022, 17:34.

Change

Previous filing in this sequence was filed on 21 Jul 2022.
Current net transaction value: -$2,127.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNXQ transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,500
Change %: +5.3%
Price
Shares after: 249,606
Date: 03 Aug 2022
Ownership: Direct
Footnotes: F1

ATNXQ transaction

Common Stock

Tax liability

Transaction value: $2,127
Shares: -3,663
Change %: -1.5%
Price: $0.5806^*
Shares after: 245,943
Date: 03 Aug 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNXQ transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: +12,500
Change %: +50%
Price: $0.000000
Shares after: 37,500
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price
Footnotes: F1, F5

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 150,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $9.00

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 211,820
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 211,820
Exercise price: $11.00

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $17.30

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $13.17
Footnotes: F2

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $12.45
Footnotes: F3

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $3.80
Footnotes: F4

ATNXQ holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 150,000
Date: 03 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.6655
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of stock.

Footnote F2

This option vests in four equal annual installments beginning on February 28, 2020.

Footnote F3

This option vests in four equal annual installments beginning on June 5, 2021.

Footnote F4

This option vests in four equal annual installments beginning on August 3, 2022.

Footnote F5

The restricted stock units vest in four equal annual installments beginning on August 3, 2022.

Footnote F6

This option vests in four equal annual installments beginning on July 20, 2023.

SEC remarks

COO, and President, Athenex Pharmaceutical Division.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .